Serum markers for fibrosis and plasma transforming growth factor-β1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 5, 1996, Pages 443-450

  Murawaki, Yoshikazu ^a   Ikuta, Yujiro ^a   Nishimura, Yuuko ^a   Koda, Masahiko ^a   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Procollagen type III propeptide; Prolyl hydroxylase; Tissue inhibitor of metalloproteinase 1; Type IV collagen 7S domain

Indexed keywords

COLLAGEN TYPE 4; MARKER; METALLOPROTEINASE INHIBITOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROPYL HYDROXYLASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029878808     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00289.x     Document Type: Article

References (36)

1. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993; 73: 161-95.
2. Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993; 7: 1434-41.
3. Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M, ed. Connective Tissue in Health and Disease. Boca Raton: CRC Press, Inc., 1990; 61-98.
4. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin. Biochem. 1991; 24: 219-39.
5. Murawaki Y, Kusakabe Y, Hirayama C. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology 1991; 14: 1167-73.
6. Murawaki Y, Koda M, Yamada S, Kawasaki H, Shima H, Burkhardt H. Serum collagenase activity in patients with chronic liver disease J. Hepatol. 1993; 18: 328-34.
7. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relation to liver histology. Hepatology 1994; 20: 780-7.
8. Keiser HR, Vogel CL, Sadikali F. Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma. J. Natl Cancer Inst. 1972; 49: 1251-5.
9. Bolarin DM, Savolainen E-R, Kivirikko KI. Enzymes of collagen synthesis and type III procollagen aminopropeptide in serum from Nigerians with hepatocellular carcinoma and other malignant diseases. Int. J. Cancer 1982; 29: 401-5.
10. Hatahara T, Igarashi S, Funaki N. High concentrations of N-terminal peptide of type III procollagen in the sera of patients with various cancers, with special reference to liver cancer. Gann 1984; 75: 130-5.
11. Suzuki M, Suzuki H, Kato Y, Okabe K, Uchikoshi T, Okazaki N. Serum and tissue prolyl hydroxylase (PH) in hepatocellular carcinoma and gastrointestinal cancer. Jpn J. Gastroenterol. 1988; 85: 2232-8.
12. Ichida T, Miyagiwa M, Inoue K et al. Diagnostic value of serum laminin, type IV collagen peptide, collagenase inhibitor and prolyl hydroxylase on HCC. In: Sung JL, Chen DS, eds. Viral Hepatitis and Hepatocellular Carcinoma. Hong Kong: Excerpta Medica Asia Ltd, 1988; 579-89.
13. Igarashi S, Funaki N, Hatahara T, Inoue T. Clinical significance of the assay of 7S and type IV collagen in the sera of patients with various liver diseases: Comparison with PIIIP and laminin P1 concentrations. Acta Hepatol. Jpn 1990; 31: 524-30 (in Japanese).
14. Yamada S, Suou T, Kawasaki H, Yoshikawa N. Clinical significance of serum 7S collagen in various liver diseases. Clin. Biochem. 1992; 25: 467-70.
15. Suou T, Yamada S, Kobayashi J, Hoshino U, Nishimuki E, Kawasaki H. Changes of serum 7S fragment of type IV collagen and N-terminal propeptide of type III procollagen after transcatheter arterial embolization as a model of acute liver injury. Hepatology 1993; 18: 809-15.
16. Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin. Chim. Acta 1993; 218: 47-58.
17. Muzzillo DA, Imoto M, Fukuda Y et al. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J. Gastroenterol. Hepatol. 1993; 8: 437-41.
18. Lissoos TW, Davis BH. Pathogenesis of hepatic fibrosis and the role of cytokines. J. Clin. Gastroenrerol. 1992; 15: 64-8.
19. Clement B, Loreal O, Leravasseur F, Guillouzo A. New challenges in hepatic fibrosis. J. Hepatol. 1993; 18: 1-4.
20. 1 in human fat-storing cells. Gastroenterology 1993; 105: 245-53.
21. 1 mRNA in human hepatocellular carcinoma. Jpn. J. Cancer Res. 1990; 81: 1202-5.
22. Ito N, Kawata S, Tamura S et al. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res. 1991; 51: 4080-3.
23. Shirai Y, Kawata S, Ito N et al. Elevated levels of plasma transforming growth-β in patients with hepatocellular carcinoma. Jpn J. Cancer Res. 1992; 83: 676-9.
24. 1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases. Cancer 1994; 73: 2275-9.
25. Yoshida S, Bai Y, Muragaki Y et al. A sandwich immunoassay for human prolyl 4-hydroxylase using monoclonal antibody. Clin. Chim. Acta 1986; 160: 37-46.
26. Shahin M, Schuppan D, Waldherr R et al. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 1992; 15: 637-44.
27. Misaki M, Shima T, Tano Y et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin. Chem. 1990; 36: 522-4.
28. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. J. Immunol. Methods 1990; 127: 103-8.
29. Bolarin D, Andy JJ, Alabi ZO. Liver immunoreactive prolyl hydroxylase protein in human primary hepatocellular carcinoma. Hepato-gastroenterol. 1983; 30: 230-2.
30. Kojoh K. Clinical significance of type III procollagen N-peptide in various liver diseases. Kawasaki Igaku Shi 1986; 12: 301-9.
31. Sakakibara K, Igarashi S, Hatahara T. Localization of type III procollagen aminopeptide antigenicity in hepatocytes from cirrhotic human liver. Virchow's Arch. Pathol. Anat. 1985; 408: 219-228.
32. Nakatsukasa H. Type IV collagen-degrading enzyme activity in hepatocellular carcinoma. Acta Med. Okayama 1986; 40: 83-91.
33. Hashimoto N, Kobayashi M, Tsuji T. Serum type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis. Acta Med. Okayama 1988; 42: 1-6.
34. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell. Mol. Biol. 1992; 7: 120-5.
35. Barsky SH, Gopalakrishna R. High metalloproteinase inhibitor content of human cirrhosis and its possible conference of metastasis resistence. J. Natl Cancer Inst. 1988; 80: 102-8.
36. Fukuda Y, Imoto M, Koyama Y et al. Immunohistochemical study on tissue inhibitors of metalloproteinases in normal and pathological human livers. Gastroenterol. Jpn 1991; 26: 37-41.